Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 35,371 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Premature Labor
Interventions: Abdominal fetal/maternal monitoring; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: E/C/F/TAF, E/C/F/TAF (Low Dose); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more

Conditions: Healthy Participants
Interventions: Plixorafenib, Cobicistat; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pneumococcal Disease
Interventions: Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control, 13vPnC, PCV15; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 18
States / cities: Tustin, California • Walnut Creek, California • Milford, Connecticut + 12 more

Conditions: Incipient Interproximal Caries
Interventions: 0.05% Sodium Fluoride with Self-Assembling Peptides; Drug
Lead sponsor: Tripler Army Medical Center; Federal
Eligibility: 18 Years to 74 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Schofield Barracks, Hawaii

Conditions: AMI
Interventions: Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Triple Negative Breast Cancer
Interventions: ribociclib, Bicalutamide; Drug
Lead sponsor: Kari Wisinski; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 6
States / cities: Chicago, Illinois • Lansing, Michigan • New Brunswick, New Jersey + 3 more

Conditions: Healthy
Interventions: amikacin/fosfomycin; Drug
Lead sponsor: Cardeas Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stroke, Acute, Stroke, Hemiparesis
Interventions: NMES device with EMG-triggered and Cyclic capabilities; Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 21 Years to 89 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: Akron, Ohio • Cincinnati, Ohio • Cleveland, Ohio

Conditions: Trichotillomania
Interventions: Habit Reversal Training; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 7 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Healthy
Interventions: PF-04308515, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Rheumatoid Arthritis
Interventions: Veltuzumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: La Mesa, California • Los Angeles, California • Upland, California + 5 more

Conditions: Myelodysplastic Syndromes
Interventions: Azacitidine Level 1, Azacitidine Level 0, Iadademstat Level 1, Iadademstat Level 0; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Metastatic Breast Cancer
Interventions: 17B-estradiol, Letrozole, Anastrozole, Exemestane; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire

Conditions: Hyperoxaluria, Primary
Interventions: Oxabact OC5 - Oxalobacter formigenes Strain HC-1; Biological
Lead sponsor: OxThera; Industry
Eligibility: 3 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Birinapant, Carboplatin, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: EBV Infection, CMV Infection, Adenoviral Infection
Interventions: Trivirus-Specific CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Alcohol Use Disorder
Interventions: Suvorexant 10 mg, Placebo; Drug · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Adult Subjects
Interventions: Pegilodecakin; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Musculoskeletal Disease
Interventions: Acceptance and Committment Therapy; Behavioral
Lead sponsor: University of New Hampshire; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, New Hampshire

Conditions: Acne Vulgaris
Interventions: Adapalene, Differin®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Concussion
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 38 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Volunteers
Interventions: LOXO-305, Itraconazole, Rifampin; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

Performance of the Monica Novii Wireless Patch System in Pre-term Labor

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Can SAP P11-4 Affect The Appearance of Interproximal Cavities on an X-ray in a Military Population

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Ribociclib and Bicalutamide in AR+ TNBC

Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers

Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke

Habit Reversal Training for Children and Adolescents With Trichotillomania

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

ER Reactivation Therapy for Breast Cancer

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

Acceptance and Commitment Therapy, a Mindfulness-Based Approach for Treatment of Chronic Musculoskeletal Pain

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

EEG Diagnostic for Repetitive Sub-concussive Head Impacts

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants